TrialJournal for immunotherapy of cancer2024

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.

Brenda C O'Connell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.